Patent ID: 9435812
Filing Date: 2016-09-06
CPC Classification: C12Q,G01N

Claim Text:
1. A method for determining risk that a prostate cancer will penetrate the prostatic capsule, comprising: contacting a prostate cancer sample isolated from a subject with an ETS related gene (ERG)-specific antibody and a phosphatase and tensin homolog (PTEN)-specific antibody; measuring increased protein expression of ERG in the prostate cancer sample relative to a control representing ERG protein expression expected in a normal prostate sample; measuring decreased PTEN in the prostate cancer sample relative to a control representing PTEN protein expression expected in a normal prostate sample; determining that there is a higher risk that the prostate cancer has penetrated or will likely penetrate the prostatic capsule based on the ERG measuring and the PTEN measuring; and administering a therapeutic agent for treating prostate cancer to the subject from which the prostate cancer sample was obtained, performing a prostatectomy on the subject from which the prostate cancer sample was obtained, or combinations thereof.